Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study
- PMID: 25832470
- PMCID: PMC4415988
- DOI: 10.1007/s12325-015-0199-z
Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study
Abstract
Introduction: Adherence to diabetes medication has been linked to improved glycemic levels and lower costs, but previous research on adherence has typically involved oral antidiabetic medication or insulin. This study examines how adherence and persistence to once-daily liraglutide impact glycemic control and economic outcomes in a real-world population of adult type 2 diabetes (T2D) patients.
Methods: A retrospective cohort study using administrative claims data from July 2009 through September 2013. Patients aged ≥18 years with T2D treated with liraglutide were identified (index date = first liraglutide prescription). Adherence was based on the proportion of days covered (PDC); with PDC ≥0.80 classified as adherent. Non-persistent patients were those with a gap in therapy of >90 days. Lab results for glycated hemoglobin (A1C) were used to identify whether patients achieved target levels of <7.0% and ≤ 6.5%, or experienced a reduction of ≥1.0% in A1C from pre-index (baseline) to post-index (follow-up). Logistic regression was used to estimate the likelihood of achieving the A1C goals, adjusted for baseline characteristics. Diabetes-related medical, pharmacy, and total costs were modeled and estimated for the adherence and persistence cohorts.
Results: A total of 1321 patients were identified. The mean PDC was 0.59 and 34% of patients were classified as adherent, while 60% were persistent over 12 months of follow-up. Adherent and persistent patients were more likely to achieve each of the A1C goals than their non-adherent and non-persistent counterparts after adjusting for patient characteristics. Adherence and persistence were associated with higher adjusted diabetes-related pharmacy and total healthcare costs during follow-up; whereas persistent patients had significantly lower diabetes-related medical costs than non-persistent patients.
Conclusions: Adherence and persistence to liraglutide are associated with improved A1C outcomes. Persistent patients showed significantly lower medical costs versus those discontinuing liraglutide. Total healthcare costs were higher for adherent and persistent cohorts driven by higher pharmacy costs.
Figures
Similar articles
-
Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.Diabetes Obes Metab. 2019 Apr;21(4):920-929. doi: 10.1111/dom.13603. Epub 2019 Jan 9. Diabetes Obes Metab. 2019. PMID: 30520248 Free PMC article.
-
Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States.J Med Econ. 2016;19(4):403-13. doi: 10.3111/13696998.2015.1131703. Epub 2016 Jan 8. J Med Econ. 2016. PMID: 26653068
-
Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.Clin Ther. 2016 Jan 1;38(1):149-60. doi: 10.1016/j.clinthera.2015.11.017. Epub 2015 Dec 17. Clin Ther. 2016. PMID: 26706658
-
Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review.Diabetes Obes Metab. 2022 Mar;24(3):377-390. doi: 10.1111/dom.14603. Epub 2021 Dec 9. Diabetes Obes Metab. 2022. PMID: 34779107 Free PMC article. Review.
-
The economic rationale for adherence in the treatment of type 2 diabetes mellitus.Am J Manag Care. 2012 Apr;18(3 Suppl):S43-8. Am J Manag Care. 2012. PMID: 22558941 Review.
Cited by
-
Greater persistence and adherence to basal insulin therapy is associated with lower healthcare utilization and medical costs in patients with type 2 diabetes: a retrospective database analysis.BMJ Open Diabetes Res Care. 2024 Mar 4;12(2):e003825. doi: 10.1136/bmjdrc-2023-003825. BMJ Open Diabetes Res Care. 2024. PMID: 38442988 Free PMC article.
-
Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China.Patient Relat Outcome Meas. 2023 Sep 26;14:253-267. doi: 10.2147/PROM.S400389. eCollection 2023. Patient Relat Outcome Meas. 2023. PMID: 37789883 Free PMC article.
-
Detecting Medication-Taking Gestures Using Machine Learning and Accelerometer Data Collected via Smartwatch Technology: Instrument Validation Study.JMIR Hum Factors. 2023 May 4;10:e42714. doi: 10.2196/42714. JMIR Hum Factors. 2023. PMID: 37140971 Free PMC article.
-
Real-World Evaluation of GLP-1 Receptor Agonist Therapy Persistence, Adherence and Therapeutic Inertia Among Obese Adults with Type 2 Diabetes.Diabetes Ther. 2023 Apr;14(4):723-736. doi: 10.1007/s13300-023-01382-9. Epub 2023 Feb 27. Diabetes Ther. 2023. PMID: 36847952 Free PMC article.
-
A Study on Weight Loss Cause as per the Side Effect of Liraglutide.Cardiovasc Ther. 2022 Dec 2;2022:5201684. doi: 10.1155/2022/5201684. eCollection 2022. Cardiovasc Ther. 2022. PMID: 36540096 Free PMC article.
References
-
- Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. In: Department of Health and Human Services, editor. Atlanta, GA. 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-.... Accessed 15 Nov 2015.
-
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous